ClinicalTrials.gg
RecruitingNCT05808374Updated Jun 18, 2023

Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B

A Phase 1 interventional study of HRS-5635 and HRS-5635 in Chronic Hepatitis B, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
184th of 273
85 · median 120
Started
2023
with 28 others
Phase 1
50 of 375
16 open now
Primary completion
2024-05
later than 6 of 109 live
Registered
262nd of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 184th largest by planned enrollment of the 273 interventional ones that give a count, is one of 29 that started in 2023, is one of 50 in phase 1, reaches primary completion later than 6 of the 109 other live ones, and was the 262nd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5635 in healthy adults and chronic hepatitis B. To explore the reasonable dosage of HRS-5635.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand the specific process of the test, voluntarily participate in the test, and sign the form in writing(In healthy people and chronic ).
  2. Age 18-55 (including boundary value) (In healthy people); Age 18-65 (including boundary value) (In chronic hepatitis B).
  3. Male weight ≥ 50 kg, female weight ≥ 45 kg, (BMI) 18\~28 kg/m2 (including boundary value) (In healthy people).
  4. Normal or abnormal vital signs, physical examination, laboratory examination, chest radiograph, etc. have no clinical significance(In healthy people).
  5. Subjects (including partners) are willing to voluntarily take effective measures within 6 months after screening and the last study drug administration(In healthy people).

Exclusion criteria

Exclusion Criteria:

  1. Those suffering from any clinical serious disease such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormality, or any other disease that can interfere with the test results(In healthy people).
  2. Previous history of malignant tumor(In healthy people).
  3. Those who have digestive system disease or serious digestive system disease at present or in the near future (within one month), and the researcher believes that it may affect drug absorption or have safety risk(In healthy people).
  4. Those who have serious infection, serious injury or major surgery within 3 months before administration; Those who plan to undergo surgery during the trial and within two weeks after the end of the trial(In healthy people).
  5. Serious cardiovascular and cerebrovascular diseases with clinical significance and unstable or uncontrolled conditions, including but not limited to myocardial infarction, unstable angina pectoris, heart failure, and moderate stroke((In chronic )).
  6. liver diseases caused by other causes (such as alcoholic liver disease, nonalcoholic steatohepatitis, drug-induced liver injury, alcoholic hepatitis, etc.); (In chronic hepatitis B).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    Part 1

    Single Dose Incremental (SAD) Trial - Healthy Persons:HRS-5635 vs. Placebo

    Drug: HRS-5635 · Drug: Placebo

  • Experimental
    Part 2a

    Multiple Dose Increase (MAD) Study - Patients Receiving Consolidation Therapy:HRS-5635 vs. Placebo

    Drug: HRS-5635 · Drug: Placebo

  • Experimental
    Part 2b

    Patients not receiving consolidation treatment:HRS-5635 vs. Placebo

    Drug: HRS-5635 · Drug: Placebo

Interventions

  • 50mg HRS-5635;100mg HRS-5635;200mg HRS-5635;400mg HRS-5635;600mg HRS-5635;800mg HRS-5635

  • 100mg HRS-5635,Q4W;200mg HRS-5635 ,Q4W;400mg HRS-5635,Q4W;200mg HRS-5635, Q2W

  • 200mg HRS-5635,Q4W

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events In Part 1

    A summary of adverse events, including Serious Adverse Events(SAEs)

    Time frame: 85 days

  2. Number of Adverse Events In Part 2

    A summary of adverse events, including Serious Adverse Events(SAEs)

    Time frame: 169 days

Secondary outcomes

  1. Peak Plasma Concentration (Cmax) of single dose

    Time frame: 8 days

  2. Peak Plasma Concentration (Cmax) of Multiple ascending dose

    Time frame: 64 days

  3. Time to the peak plasma concentration (Tmax) of single dose

    Time frame: 8 days

  4. Time to the peak plasma concentration (Tmax) of Multiple ascending dose

    Time frame: 64 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for May 2024, 13 months after the start.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 13 months is below that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2023
First posted
Apr 11, 2023
StartActual
Apr 30, 2023
Primary completionEst.
May 31, 2024
CompletionEst.
May 31, 2024
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05808374
Responsible party
Sponsor
First posted
Apr 11, 2023
Start date
Apr 30, 2023
Primary completion
May 31, 2024 (estimated)
Completion
May 31, 2024 (estimated)
Last update
Jun 18, 2023

Study contacts

Guangming Feng
Contact
guangming.feng@hengrui.com
+0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-5635

Start the discussion